Clinical application of a 3-dimensional morphometric apparatus for diagnosis and treatment of a Class III patient with facial asymmetry: A pilot study

A review of the studies on the use of the antigen-antibody system HMW-MAA 225.28S in melanoma radioimmunodetection is reported. The results obtained in a pilot study (42 patients with 74 lesions), a multicenter trial (254 patients with 553 lesions) and a prospective study still outstanding (29 patients with 38 lesions) allow to consider this system as suitable for clinical application. F(ab′)2 labelled with 99mTc gave the best results in terms of positivity. Moreover this radioisotope allows the best dosimetric conditions. The gamma energy emitted by this radionuclide is particularly convenient for conventional scintillation cameras and ECT. Very good results in terms of sensitivity (70%-85%) and especially specificity (about 100%) were achieved. Possible clinical applications of the method are discussed.

Download Full-text

The clinical application of the novel diagnosis and treatment flowchart for peri-implantitis: Part 3 clinical application on severe case

10.26226/morressier.5ac3831d2afeeb00097a3e6c ◽

2018 ◽

Author(s):

Yoichi Taniguchi

Keyword(s):

Clinical Application ◽

Severe Case ◽

Diagnosis And Treatment ◽

The Novel

Download Full-text

NT-PROBNP AND THE CUT-OFF VALUE IN CARDIOVASCULAR DISEASES

Journal of Medicine and Pharmacy ◽

10.34071/jmp.2011.5.1 ◽

2011 ◽

pp. 5-12

Author(s):

Anh Tien Hoang ◽

Van Minh Huynh ◽

Khanh Hoang ◽

Huu Dang Tran ◽

Viet An Tran

Keyword(s):

Heart Failure ◽

Cardiovascular Disease ◽

Pilot Study ◽

Cardiovascular Diseases ◽

Clinical Application ◽

European Society ◽

The Other ◽

Cardiac Marker ◽

Cardiac Biomarker ◽

European Society Of Cardiology

NT-ProBNP is a high value cardiac biomarker and widely applies in many cardiovascular diseases. The evaluation of concentration of NT-ProBNP needs the concern about age, gender, obesity and especially we need each cut-off point for each cause of cardiovascular disease in evaluation and clinical application. Because NT-ProBNP is a new cardiac marker and has been researched in 5 recent years, the cut-off of NT-ProBNP is still being studied for the clinical application in cardiovascular diseases. Only the cut-off of NT-ProBNP in diagnosis heart failure was guided by European Society of Cardiology. The meaning of introduce cut-off value of value plays an role as pilot study for the other relate study and brings the NT-ProBNP closely approach to clinical application.

Download Full-text

Cone-Beam Computed Tomography Assessment of Lower Facial Asymmetry in Unilateral Cleft Lip and Palate and Non-Cleft Patients with Class III Skeletal Relationship

PLoS ONE ◽

10.1371/journal.pone.0130235 ◽

2015 ◽

Vol 10 (8) ◽

pp. e0130235 ◽

Cited By ~ 8

Author(s):

Yifan Lin ◽

Gui Chen ◽

Zhen Fu ◽

Lian Ma ◽

Weiran Li

Keyword(s):

Computed Tomography ◽

Cone Beam Computed Tomography ◽

Cleft Lip ◽

Cleft Lip And Palate ◽

Facial Asymmetry ◽

Cone Beam ◽

Class Iii

Download Full-text

Does maxillary yaw exist in patients with skeletal Class III facial asymmetry?

American Journal of Orthodontics and Dentofacial Orthopedics ◽

10.1016/j.ajodo.2020.05.025 ◽

2021 ◽

Author(s):

Hyung-Kyu Noh ◽

Hyo-Sang Park

Keyword(s):

Facial Asymmetry ◽

Class Iii ◽

Skeletal Class

Download Full-text

Clinical Application of a Hybrid RapidArc Radiotherapy Technique for Locally Advanced Lung Cancer

Technology in Cancer Research & Treatment ◽

10.1177/1533034616670273 ◽

2016 ◽

Vol 16 (2) ◽

pp. 224-230

Author(s):

Scott R. Silva ◽

Murat Surucu ◽

Jennifer Steber ◽

Matthew M. Harkenrider ◽

Mehee Choi

Keyword(s):

Lung Cancer ◽

Clinical Application ◽

Locally Advanced ◽

Significant Risk ◽

Conformal Radiotherapy ◽

Concurrent Chemotherapy ◽

Advanced Lung Cancer ◽

3 Dimensional ◽

Contralateral Lung ◽

Locally Advanced Lung Cancer

Objective: Radiation treatment planning for locally advanced lung cancer can be technically challenging, as delivery of ≥60 Gy to large volumes with concurrent chemotherapy is often associated with significant risk of normal tissue toxicity. We clinically implemented a novel hybrid RapidArc technique in patients with lung cancer and compared these plans with 3-dimensional conformal radiotherapy and RapidArc-only plans. Materials/Methods: Hybrid RapidArc was used to treat 11 patients with locally advanced lung cancer having bulky mediastinal adenopathy. All 11 patients received concurrent chemotherapy. All underwent a 4-dimensional computed tomography planning scan. Hybrid RapidArc plans concurrently combined static (60%) and RapidArc (40%) beams. All cases were replanned using 3- to 5-field 3-dimensional conformal radiotherapy and RapidArc technique as controls. Results: Significant reductions in dose were observed in hybrid RapidArc plans compared to 3-dimensional conformal radiotherapy plans for total lung V20 and mean (−2% and −0.6 Gy); contralateral lung mean (−2.92 Gy); and esophagus V60 and mean (−16.0% and −2.2 Gy; all P < .05). Contralateral lung doses were significantly lower for hybrid RapidArc plans compared to RapidArc-only plans (all P < .05). Compared to 3-dimensional conformal radiotherapy, heart V60 and mean dose were significantly improved with hybrid RapidArc (3% vs 5%, P = .04 and 16.32 Gy vs 16.65 Gy, P = .03). However, heart V40 and V45 and maximum spinal cord dose were significantly lower with RapidArc plans compared to hybrid RapidArc plans. Conformity and homogeneity were significantly better with hybrid RapidArc plans compared to 3-dimensional conformal radiotherapy plans ( P < .05). Treatment was well tolerated, with no grade 3+ toxicities. Conclusion: To our knowledge, this is the first report on the clinical application of hybrid RapidArc in patients with locally advanced lung cancer. Hybrid RapidArc permitted safe delivery of 60 to 66 Gy to large lung tumors with concurrent chemotherapy and demonstrated advantages for reduction in low-dose lung volumes, esophageal dose, and mean heart dose.

Download Full-text